Loading
A phase 3 trial of Izalontamab brengitecan, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) is a phase 3 interventional study registered as NCT06382116 by Sichuan Baili Pharmaceutical Co., Ltd., with 432 participants enrolled, started 2024-05-22 and due to reach its primary completion in 2026-08. Interventions recorded: BL-B01D1, Pemetrexed+Cisplatin or Carboplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Pemetrexed, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Pemetrexed, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.